Opioids and Traffic Safety – Focus on Buprenorphine

Abstract

Background:

Opioid maintenance therapy is a well-established first-line treatment approach in opioid dependence. The effects of opioids such as buprenorphine on cognitive functioning and driving ability are a matter of debate.

Objectives:

A comprehensive review of studies of the effects of buprenorphine on traffic safety is presented.

Results:

A number of recent epidemiological and road surveys indicate that opioids have a moderate risk for causing accidents compared to other drugs of abuse, such as alcohol. A number of neuropsychological studies, a few of which were prospective and used a randomized control group, have used standardized test batteries to measure domains relevant for psychomotor functioning and driving ability. Single doses of buprenorphine have been shown to induce some impairment in healthy volunteers, but less than found in chronic users. Some non-randomized studies indicate somewhat better cognitive performance of patients on buprenorphine than of those on methadone but this finding has not been demonstrated in randomized controlled trials.

Conclusions:

Opioids as a class of drugs induce some impairment of driving ability, but less than other psychotropic agents or drugs of abuse. Personality features such as impulsivity, sensation seeking, low risk perception and antisocial behaviour, comorbid psychiatric and neurological disorders and additional substance use of opioid users are of relevance for traffic safety. Buprenorphine does not cause more cognitive impairment than methadone or may even cause less. Caution is required when initiating treatment with buprenorphine. The risk for driving ability impairment is probably less under steady state conditions. Finally, higher doses of buprenorphine are probably not associated with more impairment.

Key words

opioids - opioid dependence - buprenorphine - cognition - driving ability

• References

• 1 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) . Annual report on the state of the drugs problem in Europe. Lisbon: EMCDDA; 2011
• 2 United Nations Office on Drugs and Crime . 2006 World Drug Report. Vienna: UNODC; 2006
• 3 Hser YI, Hoffman V, Grella CE et al. 33-year follow-up of narcotics addicts. Arch Gen Psychiatry 2001; 58: 503-508
• 4 Termorshuizen F, Krol A, Prins M et al. Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users. Am J Epidemiol 2005; 161: 271-279
• 5 Connock M, Juarez-Garcia A, Jowett S et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1-171 iii–iv
• 6 Kleber HD, Weiss RD, Anton Jr RF et al. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry 2007; 164: 5-123
• 7 Lingford-Hughes AR, Welch S, Peters L et al. BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 2012; 26: 899-952
• 8 Soyka M, Kranzler HR, van den Brink W et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry 2011; 12: 160-187
• 9 Gruber SA, Silveri MM, Yurgelun-Todd DA. Neuropsychological consequences of opiate use. Neuropsychol Rev 2007; 17: 299-315
• 10 Mattick RP, Ali R, White JM et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98: 441-452
• 11 Mattick RP, Breen C, Kimber J et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; CD002209
• 12 Mattick RP, Kimber J, Breen C et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; CD002207
• 13 Mammen K, Bell J. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence. Expert Opin Pharmacother 2009; 10: 2537-2544
• 14 Soyka M, Trader A, Klotsche J et al. Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. J Forensic Sci 2012; 57: 1524-1530
• 15 Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. drug Alcohol Rev 2004; 23: 319-344
• 16 Penning R, Veldstra JL, Daamen AP et al. Drugs of Abuse, driving and traffic safety. Curr Drug Abuse Rev 2010; 3: 23-32
• 17 Strand MC, Fjeld B, Arnestad M et al. Can patients receiving opioid maintenance therapy safely drive? A systematic review of epidemiological and experimental studies on driving ability with a focus on concomitant methadone or buprenorphine administration. Traffic Inj Prev 2013; 14: 26-38
• 18 Corsenac P, Lagarde E, Gadegbeku B et al. Road traffic crashes and prescribed methadone and buprenorphine: a French registry-based case-control study. Drug Alcohol Depend 2012; 123: 91-97
• 19 Callaghan RC, Gatley JM, Veldhuizen S et al. Alcohol- or drug-use disorders and motor vehicle accident mortality: a retrospective cohort study. Accid Anal Prev 2013; 53: 149-155
• 20 Monarrez-Espino J, Moller J, Berg HY et al. Analgesics and road traffic crashes in senior drivers: An epidemiological review and explorative meta-analysis on opioids. Accid Anal Prev 2013; 57: 157-164
• 21 Gomes T, Redelmeier DA, Juurlink DN et al. Opioid dose and risk of road trauma in Canada: a population-based study. JAMA Intern Med 2013; 173: 196-201
• 22 Legrand SA, Silverans P, de Paepe P et al. Presence of psychoactive substances in injured Belgian drivers. Traffic Inj Prev 2013; 14: 461-468
• 23 Dassanayake T, Michie P, Carter G et al. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011; 34: 125-156
• 24 Hels T, Lyckegaard A, Simonsen KW et al. Risk of severe driver injury by driving with psychoactive susbtances. Accid Anal Prev 2013; 59: 346-356
• 25 Bukten A, Herskedal A, Skurtveit S et al. Driving under the influence (DUI) among patients in opioid maintenance treatment (OMT): a registry-based national cohort study. Addiction 2013;
• 26 Pluck G, Lee KH, Rele R et al. Premorbid and current neuropsychological function in opiate abusers receiving treatment. Drug Alcohol Depend 2012; 124: 181-184
• 27 Darke S, McDonald S, Kaye S et al. Comparative patterns of cognitive performance amongst opioid maintenance patients, abstinent opioid users and non-opioid users. Drug Alcohol Depend 2012; 126: 309-315
• 28 Soyka M, Trader A, Klotsche J et al. Six-year mortality rates of patients in methadone and buprenorphine maintenance therapy: results from a nationally representative cohort study. J Clin Psychopharmacol 2011; 31: 678-680
• 29 Kamien JB, Branstetter SA, Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: a randomised double-blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl 2008; 10: 5-18
• 30 Ling W, Wesson DR, Charuvastra C et al. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53: 401-407
• 31 Schottenfeld RS, Pakes JR, Oliveto A et al. Buprenorphine vs. methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54: 713-720
• 32 Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence. Eur Neuropsychopharmacol 2004; 14: 209-216
• 33 Kraus ML, Alford DP, Kotz MM et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med 2011; 5: 254-263
• 34 Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs. buprenorphine in France. JAMA 2001; 285: 45
• 35 Pirnay S, Borron SW, Giudicelli CP et al. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 2004; 99: 978-988
• 36 Mintzer MZ, Copersino ML, Stitzer ML. Opioid abuse and cognitive performance. Drug Alcohol Depend 2005; 78: 225-230
• 37 Prosser J, Cohen LJ, Steinfeld M et al. Neuropsychological functioning in opiate-dependent subjects receiving and following methadone maintenance treatment. Drug Alcohol Depend 2006; 84: 240-247
• 38 Roncero C, Alavrez FJ, Barral C et al. Driving and legal status of Spanish opioid-dependent patients. Substance Abuse Treatment Prev Policy 2013; 8: 19
• 39 Bachoo S, Bhagwanjee A, Govender K. The influence of anger, impulsivity, sensation seeking and driver attitudes on risky driving behaviour among post-graduate university students in Durban, South Africa. Accid Anal Prev 2013; 55: 67-76
• 40 Brandau H, Daghofer F, Hofmann M et al. Personality subtypes of young moped drivers, their relationship to risk-taking behavior and involvement in road crashes in an Austrian sample. Accid Anal Prev 2011; 43: 1713-1719
• 41 Constantinou E, Panayiotou G, Konstantinou N et al. Risky and aggressive driving in young adults: Personality matters. Accid Anal Prev 2011; 43: 1323-1331
• 42 Jakubczyk A, Klimkiewicz A, Wnorowska A et al. Impulsivity, risky behaviors and accidents in alcohol-dependent patients. Accid Anal Prev 2013; 51: 150-155
• 43 Lev D, Hershkovitz E, Yechiam E. Decision making and personality in traffic offenders: a study of Israeli drivers. Accid Anal Prev 2008; 40: 223-230
• 44 Richer I, Bergeron J. Driving under the influence of cannabis: links with dangerous driving, psychological predictors, and accident involvement. Accid Anal Prev 2009; 41: 299-307
• 45 Ryb GE, Dischinger PC, Kufera JA et al. Risk perception and impulsivity: association with risky behaviors and substance abuse disorders. Accid Anal Prev 2006; 38: 567-573
• 46 Walsh JM, Verstraete AG, Huestis MA et al. Guidelines for research on drugged driving. Addiction 2008; 103: 1258-1268
• 47 Fishbain DA, Cutler RB, Rosomoff HL et al. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003; 25: 559-577
• 48 Mintzer MZ. Effects of opioid pharmacotherapy on psychomotor and cognitive performance: A review of human laboratory studies of methadone and buprenorphine. Heroin Addiction and Related Clinical Problems 2007; 9: 5-24
• 49 Morland J. Maintenance treatment and car driving. Maintenance treatment of heroin addiction: evidence at the crossroads. Oslo: Cappelen Akademisk Forlag; 2003. 254-264
• 50 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) . Driving Under the influence of Drugs, Alcohol and Medicines in Europe – findings from the DRUID project. Lisbon: EMCDDA; 2012
• 51 Mailis-Gagnon A, Lakha SF, Furlan A et al. Systematic review of the quality and generalizability of studies on the effects of opioids on driving and cognitive/psychomotor performance. Clin J Pain 2012; 28: 542-555
• 52 Orriols L, Salmi LR, Philip P et al. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies. Pharmacoepidemiol Drug Saf 2009; 18: 647-658
• 53 Rapoport MJ, Lanctot KL, Streiner DL et al. Benzodiazepine use and driving: a meta-analysis. J Clin Psychiatry 2009; 70: 663-673
• 54 Elvik R. Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2012; Jul 9.
• 55 Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012; 344: e536
• 56 Li MC, Brady JE, DiMaggio CJ et al. Marijuana use and motor vehicle crashes. Epidemiol Rev 2012; 34: 65-72
• 57 Engeland A, Skurtveit S, Morland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol 2007; 17: 597-602
• 58 Gibson JE, Hubbard RB, Smith CJ et al. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol 2009; 169: 761-768
• 59 Leveille SG, Buchner DM, Koepsell TD et al. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994; 5: 591-598
• 60 Movig KL, Mathijssen MP, Nagel PH et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 2004; 36: 631-636
• 61 Bachs LC, Engeland A, Morland JG et al. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or tramadol. Clin Pharmacol Ther 2009; 85: 596-599
• 62 Blomberg RD, Preusser DF. Narcotic use and driving behavior. Accid Anal Prev 1974; 6: 23-32
• 63 Maddux JF, Williams TR, Ziegler JA. Driving records before and during methadone maintenance. Am J Drug Alcohol Abuse 1977; 4: 91-100
• 64 Babst DV, Newman S, Gordon NB et al. Driving records of methadone maintenance patients in New York State. J Drug Issues 1973; 3: 285-292
• 65 Bramness JG, Skurtveit S, Morland J et al. An increased risk of motor vehicle accidents after prescription of methadone. Addiction 2012; 107: 967-972
• 66 Wiese Simonsen K, Steenttoft A, Bernhoft IM et al. Psychoactive substances in seriously injured drivers in Denmark. Forensic Sci Int 2013; 224: 44-50
• 67 Loeber S, Nakovics H, Kniest A et al. Factors affecting cognitive function of opiate-dependent patients. Drug Alcohol Depend 2012; 120: 81-87
• 68 Baldacchino A, Balfour DJK, Passetti F et al. Neuropsychological consequences of chronic opioid use: A quantitative review and meta-analysis. Neurosci Biobehav Rev 2012; 36: 2056-2068
• 69 van Holst RJ, Schilt T. Drug-related decrease in neuropsychological functions of abstinent drug users. Curr Drug Abuse Rev 2011; 4: 42-56
• 70 Fernandez-Serrano MJ, Perez-Garcia M, Verdejo-Garcia A. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance?. Neurosci Biobehav Rev 2011; 35: 377-406
• 71 Mintzer MZ, Stitzer ML. Cognitive impairment in methadone maintenance patients. Drug Alcohol Depend 2002; 67: 41-51
• 72 Batty GD, Mortensen EL, Osler M. Childhood IQ in relation to later psychiatric disorder: evidence from a Danish birth cohort study. Br J Psychiatry 2005; 187: 180-181
• 73 Verdejo-Garcia A, Del Mar Sanchez-Fernandez M, Alonso-Maroto LM et al. Impulsivity and executive functions in polysubstance-using rave attenders. Psychopharmacology (Berl) 2010; 210: 377-392
• 74 Verdejo-Garcia A, Perez-Garcia M, Bechara A. Emotion, decision-making and substance dependence: a somatic-marker model of addiction. Curr Neuropharmacol 2006; 4: 17-31
• 75 Ersche KD, Clark L, London M et al. Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology 2006; 31: 1036-1047
• 76 Ersche KD, Sahakian BJ. The neuropsychology of amphetamine and opiate dependence: implications for treatment. Neuoropsychology Rev 2007; 17: 317-336
• 77 Applebaum AJ, Otto MW, Richardson MA et al. Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. J Clin Exp Neuropsychol 2010; 32: 579-589
• 78 Passetti F, Clark L, Mehta MA et al. Neuropsychological predictors of clinical outcome in opiate addiction. Drug Alcohol Depend 2008; 94: 82-91
• 79 Dolcos F, Strungaru C, Dolcos SM et al. The involvement of endogenous opiates in emotional-cognitive interaction in stress. Rom J Physiol 1998; 35: 259-274
• 80 Barry D, Petry NM. Predictors of decision-making on the Iowa Gambling Task: independent effects of lifetime history of substance use disorders and performance on the Trail Making Test. Brain Cogn 2008; 66: 243-252
• 81 Petrovic P, Pleger B, Seymour B et al. Blocking central opiate function modulates hedonic impact and anterior cingulate response to rewards and losses. J Neurosci 2008; 28: 10509-10516
• 82 Davis PE, Liddiard H, McMillan TM. Neuropsychological deficits and opiate abuse. Drug Alcohol Depend 2002; 67: 105-108
• 83 Lee TM, Pau CW. Impulse control differences between abstinent heroin users and matched controls. Brain Inj 2002; 16: 885-889
• 84 Pau CW, Lee TM, Chan SF. The impact of heroin on frontal executive functions. Arch Clin Neuropsychol 2002; 17: 663-670
• 85 Verdejo-Garcia A, Perez-Garcia M. Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components. Psychopharmacology (Berl) 2007; 190: 517-530
• 86 Verdejo A, Toribio I, Orozco C et al. Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusers. Drug Alcohol Depend 2005; 78: 283-288
• 87 Fernandez-Serrano MJ, Perez-Garcia M, Schmidt Rio-Valle J et al. Neuropsychological consequences of alcohol and drug abuse on different components of executive functions. J Psychopharmacol 2010; 24: 1317-1332
• 88 Soyka M, Limmer C, Lehnert R et al. A comparison of cognitive function in patients under maintenance treatment with heroin, methadone, or buprenorphine and healthy controls: an open pilot study. Am J Drug Alcohol Abuse 2011; 37: 497-508
• 89 Curran HV, Kleckham J, Bearn J et al. Effects of methadone on cognition, mood and craving in detoxifying opiate addicts: a dose-response study. Psychopharmacology (Berl) 2001; 154: 153-160
• 90 Darke S, Sims J, McDonald S et al. Cognitive impairment among methadone maintenance patients. Addiction 2000; 95: 687-695
• 91 Lyvers M, Yakimoff M. Neuropsychological correlates of opioid dependence and withdrawal. Addict Behav 2003; 28: 605-611
• 92 Goldstein RZ, Volkow ND. Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications. Nat Rev Neurosci 2011; 12: 652-669
• 93 George O, Koob GF. Individual differences in prefrontal cortex function and the transition from drug use to drug dependence. Neurosci Biobehav Rev 2010; 35: 232-247
• 94 Karch SB. Karch’s pathology of drug abuse. 4^th ed. Boca Raton: CRC Press; 2009
• 95 Kurita GP, Sjogren P, Ekholm O et al. Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol 2011; 29: 1297-1303
• 96 Kurita GP, de Mattos Pimenta CA, Braga PE et al. Cognitive function in patients with chronic pain treated with opioids: characteristics and associated factors. Acta Anaesthesiol Scand 2012; 56: 1257-1266
• 97 Landro NI, Fors EA, Vapenstad LL et al. The extent of neurocognitive dysfunction in a multidisciplinary pain centre population. Is there a relation between reported and tested neuropsychological functioning?. Pain 2013; 154: 972-977
• 98 Michna E, Ross EL, Hynes WL et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004; 28: 250-258
• 99 Amato JN, Marie S, Lelong-Boulouard V et al. Effects of three therapeutic doses of codeine/paracetamol on driving performance, a psychomotor vigilance test, and subjective feelings. Psychopharmacology (Berl) 2013; Epub ahead of print
• 100 Soyka M. Safety aspects in methadone substitution – Part 1. Legal framework conditions, mortality, current results of treatment research. Suchtmed 2008; 10: 7-27
• 101 Soyka M. Safety aspects in methadone substitution – Part 2. Clinical-pharmacological aspects. Suchtmed 2008; 10: 119-144
• 102 Menefee LA, Frank ED, Crerand C et al. The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med 2004; 5: 42-49
• 103 Ramaekers JG. Pitfalls in estimating drug-related crash risk. Trends Pharmacol Sci 2003; 24: 114-115
• 104 Verster JC, Veldhuijzen DS, Volkerts ER. Effects of an opioid (oxycodone/paracetamol) and an NSAID (bromfenac) on driving ability, memory functioning, psychomotor performance, pupil size, and mood. Clin J Pain 2006; 22: 499-504
• 105 Andersen JM, Olaussen CF, Ripel A et al. Long-term methadone treatment impairs novelty preference in rats both when present and absent in brain tissue. Pharmacol Biochem Behav 2011; 98: 412-416
• 106 Specka M, Finkbeiner T, Lodemann E et al. Cognitive-motor performance of methadone-maintained patients. Eur Addict Res 2000; 6: 8-19
• 107 Gruber SA, Tzilos GK, Silveri MM et al. Methadone maintenance improves cognitive performance after two months of treatment. Exp Clin Psychopharmacol 2006; 14: 157-164
• 108 Soyka M, Zingg C, Koller G et al. Cognitive function in short- and long-term substitution treatment: are there differences?. World J Biol Psychiatry 2010; 11: 400-408
• 109 Bracken BK, Trksak GH, Penetar DM et al. Response inhibition and psychomotor speed during methadone maintenance: impact of treatment duration, dose, and sleep deprivation. Drug Alcohol Depend 2012; 125: 132-139
• 110 Messinis L, Lyros E, Andrian V et al. Neuropsychological functioning in buprenorphine maintained patients versus abstinent heroin abusers on naltrexone hydrochloride therapy. Hum Psychopharmacol 2009; 24: 524-531
• 111 Baewert A, Gombas W, Schindler SD et al. Influence of peak and trough levels of opioid maintenance therapy on driving aptitude. Eur Addict Res 2007; 13: 127-135
• 112 Kagerer S, Backmund M, Walcher S et al. Substitution with buprenorphine and driving ability – results of an experimental study. Suchtmed 2002; 4: 17-24
• 113 Lenne MG, Dietze P, Rumbold GR et al. The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving. Drug Alcohol Depend 2003; 72: 271-278
• 114 Loeber S, Kniest A, Diehl A et al. Neuropsychological functioning of opiate-dependent patients: a nonrandomized comparison of patients preferring either buprenorphine or methadone maintenance treatment. Am J Drug Alcohol Abuse 2008; 34: 584-593
• 115 Pirastu R, Fais R, Messina M et al. Impaired decision-making in opiate-dependent subjects: effect of pharmacological therapies. Drug Alcohol Depend 2006; 83: 163-168
• 116 Rapeli P, Fabritius C, Alho H et al. Methadone vs. buprenorphine/naloxone during early opioid substitution treatment: a naturalistic comparison of cognitive performance relative to healthy controls. BMC Clin Pharmacol 2007; 7: 5
• 117 Soyka M, Hock B, Kagerer S et al. Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial. J Clin Psychopharmacol 2005; 25: 490-493
• 118 Soyka M, Lieb M, Kagerer S et al. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. J Clin Psychopharmacol 2008; 28: 699-703
• 119 Preston KL, Bigelow GE, Liebson IA. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) 1988; 94: 484-490
• 120 Singhal A, Tripathi BM, Pal HR et al. Effect of buprenorphine on psychomotor functions in patients on buprenorphine maintenance. J Opioid Manag 2008; 4: 41-47
• 121 Strain EC, Preston KL, Liebson IA et al. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992; 261: 985-993
• 122 Strain EC, Preston KL, Liebson IA et al. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 1995; 272: 628-638
• 123 Strain EC, Walsh SL, Preston KL et al. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology (Berl) 1997; 129: 329-338
• 124 Walsh SL, June HL, Schuh KJ et al. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) 1995; 119: 268-276
• 125 Mintzer MZ, Lanier RK, Lofwall MR et al. Effects of repeated tramadol and morphine administration on psychomotor and cognitive performance in opioid-dependent volunteers. Drug Alcohol Depend 2010; 111: 265-288
• 126 Jensen ML, Sjogren P, Upton RN et al. Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. Basic Clin Pharmacol Toxicol 2008; 103: 94-101
• 127 MacDonald FC, Gough KJ, Nicoll RA et al. Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac. Br J Clin Pharmacol 1989; 27: 453-459
• 128 Manner T, Kanto J, Salonen M. Simple devices in differentiating the effects of buprenorphine and fentanyl in healthy volunteers. Eur J Clin Pharmacol 1987; 31: 673-676
• 129 Saarialho-Kere U, Mattila MJ, Paloheimo M et al. Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol 1987; 33: 139-146
• 130 Zacny JP, Conley K, Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 1997; 282: 1187-1197
• 131 Wang JH, Liu XF, Chen YM et al. Heroin impairs map-picture-following and memory tasks dependent on gender and orientation of the tasks. Behav Neurosci 2007; 121: 653-664
• 132 Brand M, Roth-Bauer M, Driessen M et al. Executive functions and risky decision-making in patients with opiate dependence. Drug Alcohol Depend 2008; 97: 64-72
• 133 Bruhn P, Maage N. Intellectual and neuropsychological functions in young men with heavy and long-term patterns of drug abuse. Am J Psychiatry 1975; 132: 397-401
• 134 Guerra D, Sole A, Cami J et al. Neuropsychological performance in opiate addicts after rapid detoxification. Drug Alcohol Depend 1987; 20: 261-270
• 135 Ornstein TJ, Iddon JL, Baldacchino AM et al. Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 2000; 23: 113-126
• 136 Pakesch G, Loimer N, Grunberger J et al. Neuropsychological findings and psychiatric symptoms in HIV-1 infected and noninfected drug users. Psychiatry Res 1992; 41: 163-177
• 137 Rapeli P, Kivisaari R, Autti T et al. Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls. BMC Psychiatry 2006; 6: 9
• 138 Fishbein DH, Krupitsky E, Flannery BA et al. Neurocognitive characterizations of Russian heroin addicts without a significant history of other drug use. Drug Alcohol Depend 2007; 90: 25-38
• 139 Mintzer MZ, Correia CJ, Strain EC. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers. Drug Alcohol Depend 2004; 74: 205-209
• 140 Leung SY. Benzodiazepines, opioids and driving: an overview of the experimental research. Drug Alcohol Rev 2011; 30: 281-286
• 141 Berghaus G, Friedel B. Methadone and driver fitness. Euro-methwork Newsletter 1998; 13: 5-6
• 142 Schindler SD, Ortner R, Peternell A et al. Maintenance therapy with synthetic opioids and driving aptitude. Eur Addict Res 2004; 10: 80-87
• 143 Soyka M, Horak M, Dittert S et al. Less driving impairment on buprenorphine than methadone in drug-dependent patients?. J Neuropsychiatry Clin Neurosci 2001; 13: 527-528
• 144 Shmygalev S, Damm M, Weckbecker K et al. The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function. Drug Alcohol Depend 2011; 117: 190-197
• 145 Sabatowski R. Driving ability under opioids: current assessment of published studies. Dtsch Med Wochenschr 2008; 133 (Suppl 2): S25-S28
• 146 Dagtekin O, Gerbershagen HJ, Wagner W et al. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients. Anesth Analg 2007; 105: 1442-1448